Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Valerie Easton"'
Autor:
Miguel Martin, Sherko Kümmel, Rebecca Dent, A. Goncalves, Javier Cortes, Florian Schuetz, Sandra M. Swain, Erika Pollex, Valerie Easton, Fabrice Andre, Peter Schmid, Regula Deurloo
Publikováno v:
Future Oncology. 15:1951-1961
The PD-L1 inhibitor atezolizumab received US FDA accelerated approval as treatment for PD-L1-positive metastatic triple-negative breast cancer (TNBC). In IMpassion130, combining atezolizumab with first-line nab-paclitaxel for metastatic TNBC signific
Autor:
Edith A. Perez, J. M. López-Vega, Martin Andersson, Thierry Petit, Valerie Easton, Claudio Zamagni, Eleonora Restuccia, Julia Kamber
Publikováno v:
The Oncologist
The final efficacy and safety results are reported for the VELVET Cohort 2 trial, which investigated the coinfusion of pertuzumab and trastuzumab in a single infusion bag, followed by vinorelbine.
Background. VELVET Cohort 1 demonstrated the app
Background. VELVET Cohort 1 demonstrated the app
Autor:
Grazia Arpino, Christopher Poole, Valerie Easton, C. Kent Osborne, Christine Wohlfarth, Jean-Marc Ferrero, Juan de la Haba-Rodriguez, Mothaffar F. Rimawi, Roberto Hegg, Sabino De Placido
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 36(28)
Purpose To assess pertuzumab plus trastuzumab and an aromatase inhibitor (AI) in patients with human epidermal growth factor receptor 2 (HER2)–positive and hormone receptor–positive metastatic/locally advanced breast cancer (MBC/LABC). Patients a
Autor:
Martin Andersson, Claudio Zamagni, Edith A. Perez, J. M. López-Vega, Valerie Easton, Thierry Petit, Julia Kamber, Eleonora Restuccia
Publikováno v:
Breast Cancer Research : BCR
Background Pertuzumab, trastuzumab, and docetaxel is standard of care for first-line treatment of HER2-positive metastatic breast cancer (MBC). However, alternative chemotherapy partners are required to align with patient/physician preferences and to
Autor:
Sandra M. Swain, Sherko Kümmel, Fabrice Andre, Erika Pollex, Peter Schmid, Javier Cortes, Miguel Martín, Anthony Gonçalves, Florian Schuetz, Rebecca Dent, Valerie Easton
Publikováno v:
Journal of Clinical Oncology. 36:TPS1115-TPS1115
TPS1115Background: Atezo blocks the interaction of PD-L1 with receptors PD-1 and B7.1, restoring anti-tumor immunity. PD-L1 pathway inhibitors may be synergistic with CT. In a phase 1b study in mTN...
Publikováno v:
British Journal of Neurosurgery. 17:29-39
Age-specific norms are necessary to determine potential secondary brain insult after head injury in children. We describe and quantify the secondary physiological derangement recorded in children of different ages following traumatic brain injury, an
Publikováno v:
Stroke. 32:1291-1297
Background and Purpose —We sought to perform a large, prospective, multicenter, blinded study comparing power transcranial color duplex sonography (power TCDS) with intra-arterial digital subtraction angiography (IADSA) in the detection of intracra
Publikováno v:
Journal of Neurology, Neurosurgery & Psychiatry. 70:101-104
The objective was to compare secondary insults, particularly decreases in jugular bulb oxyhaemoglobin saturation (SjO2), during intensive care in patients with "poor" and "good" outcomes 12months after traumatic brain injury. A prospective observatio
Autor:
Valerie Easton
Forcing flowers to stand up and do tricks is the old way of flower bouquets. That called for flying in blossoms from around the world. The new way is so much more DIY and all about what's happening in the garden right now--no matter the season. Peta
Autor:
Andreas, Engert, Henning, Bredenfeld, Hartmut, Döhner, Anthony D, Ho, Norbert, Schmitz, Dietmar, Berger, Pamela, Bacon, Tomas, Skacel, Valerie, Easton, Volker, Diehl
Publikováno v:
Haematologica. 91(4)
The primary endpoint of this feasibility study was to determine whether pegfilgrastim support could enable the delivery of the full dose of BEACOPP chemotherapy every 14 days on schedule. Forty-one patients with high-risk Hodgkin's lymphoma were rand